The clinical benefits of interferon (IFN) ␤ therapy in some multiple sclerosis (MS) patients are still unexplained, raising the question whether polymorphism within the IFNB gene itself would provide an explanation. Screening the IFNB gene by single strand conformation polymorphism (SSCP) analysis and sequencing, a single nucleotide polymorphism was identified. Both alleles were distributed with similar frequencies in MS patients and controls. 
Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with primary or secondary autoimmune pathology. 2, 3 After manifestation in early adulthood relapses are followed by remissions in 80-90% of MS patients (RRMS). Half of these patients develop a secondary progressive type of the disease (SPMS) in the following 10 years. The minority of patients (10-20%) never experiences remissions having a more severe primary progressive MS (PPMS) from the beginning. 4 Exceptionally high incidence of MS in some countries and almost resistance in others has been envisaged as strong indications for environmental agents in the manifestation of the disease. 5 Moreover migration studies indicated that exposure to environmental conditions are most effective if encountered before the age of 15 years. 6 A pathogen was never identified but the characteristics of acute MS lesions are suggestive of slow
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Financial support was provided by the Ruhr-University Bochum (FoRUM project to CH, JTE, DP), the Schering Deutschland GmbH (Berlin, Germany; project to CH) and the Serono Pharma GmbH (Unterschleissheim, Germany; project to CH). Received 21 April 1999; revised 30 April 1999; accepted 5 May 1999 or latent virus infection. Antiviral activity of interferon (IFN) was therefore believed to have a therapeutic potential in MS treatment. This hypothesis was underscored by the finding that IFN synthesis may be defective in MS patients. 7 Human IFN genes and their products are classified as type I (IFNA, IFNB genes, IFN␣, IFN␤ proteins) and type II (IFNG gene, IFN␥ protein) according to their functional and genetic properties. 8 IFN␣ and IFN␤ display distinct but similar activities and bind to the same cell surface receptors. Type I IFN genes have evolved by duplication and recombination events in a gene cluster on chromosome 9. To date 26 IFN genes and pseudogenes have been identified. 9 The IFNA genes comprise a multigene family with 13 members which may differ in their biological and immunological properties. 10 In humans only a single IFNB gene exists. Type I and II IFN's share antiviral activity but differ in almost all other characteristics; the IFNG gene is located on chromosome 12 and binds to a distinct cell surface receptor. 11 Moreover several studies have indicated not only diverse functions but also counteracting activity explaining some of the beneficial effects in type I IFN treatment. 12, 13 In vivo, IFN␣ is predominantly produced by leukocytes, in particular dendritic cells and macrophages, while IFN␤ is synthesized by a variety of cells, including fibroblasts, epithelial cells and macrophages. IFN␥ is produced by activated T cells Arnason, 1999] . 15 Attack frequency, disease activity and disease burden were markedly reduced. In the meantime it has been shown, that rIFN␤ could also lessen accumulation of disability in patients with SPMS. 16 Even though rIFN␤ seems to be one of the most efficient agents in the treatment of MS, a number of questions remain open, concerning individual dosage, long-term benefit in individual patients, side effects and the production of neutralizing antibodies (NAB). A total of 38% of MS patients treated with rIFN␤-1b (Betaferon ® ) and 22% of those treated with rIFN␤-1a (Avonex ® ) were reported to develop NABs which could reduce the clinical efficacy of the drug. Moreover these antibodies are cross-reactive. 17 As shown previously for chronic Hepatitis B patients undergoing IFN␣-2 therapy the development of NAB varies. Thus rIFN␣-2a is more immunogenic than rIFN␣-2b. 18 Both rIFN's can be viewed as allelic since they differ only in one aa. Homozygosity (IFN␣-2b [23Lys]) for the polymorphic IFN protein may circumvent tolerance induction towards the foreign (IFN␣-2a [23Arg]) recombinant protein. In fact, all individuals described so far (n = 75) are homozygous for the IFN␣-2b allele and induction of neutralizing antibodies is not surprising. 19 The clinical and immunological changes following IFN␤ therapy have been documented and numerous investigations were initiated in order to explain in vivo activities of IFN's by experimental systems in vitro. Since the function of a gene may be altered by mutations, polymorphism or sequence variations (MPSV) the present study was designed to determine the extent of polymorphism within the IFNB gene. In this study we ask: (1) if polymorphism(s) within the 5′ untranslated region (UTR) of the IFNB gene might correlate with reduced constitutive and inducible IFNB expression, (2) if polymorphism(s) within the 3′UTR would affect IFNB mRNA stability, (3) if protein polymorphism(s) within the coding region might influence receptor ligand interaction and signal transduction. In addition, the risk to produce NAB during IFN␤ therapy may correlate with IFNB protein polymorphism(s). Finally the study was performed to extent the previous work 1 ie, to determine if protection from MS in individuals carrying the IFNA [02] microsatellite allele might be explained by linkage to as yet unknown IFNB polymorphisms.
Results

Polymorphism within the IFNB gene is not associated with MS predisposition
Expression of the IFNB gene is controlled by binding of transcription factors to positive and negative regulatory domains in the 5′UTR, 20, 21 while mRNA stability is regulated by AU rich sequences in the 3′UTR. 22 Since the IFNB gene lacks introns and the unprocessed precursor is not more than 187 aa in length, three primer pairs (Table 1) were sufficient to screen the 5'UTR (368 bp), 3′UTR (327 bp) and the coding region (561 bp) for polymorphism by SSCP analysis (IFNB AC# J00218). A single C → T transition was identified at nucleotide (nt) 153, leaving the aa tyrosine in position 51 of the unprocessed precursor unchanged [Tyr51Tyr] . The allele IFNB [153T] occurred with a frequency of 38.5% in the healthy German population (n = 113) and was similar in MS patients (37%, n = 280). Comparison of the allele carrier and genotype frequencies in MS patients and controls revealed no significant association ( = NS). These data provide the first evidence for a haplotype predisposing to MS, which is characterized by polymorphisms in the IFN-region.
Polymorphism(s) within the candidate genes IFNA2, IFNA10, IFNA17 and MS predisposition
Based on more than 50 IFNA related sequences considerable genetic polymorphism has been assumed within the IFNA multigene family. 23 Out of 16 sequences confined to six different IFNA genes three polymorphisms within the IFNA10 and IFNA17 genes have been confirmed in a Swedish population. 23 In our study five presumably polymorphic sites listed in Gololeva et al 23 were selected, (1) a P = 280, C = 113; b P = 104, C = 27; c P = 69, C = 33. to confirm the polymorphisms in Germans and (2) to test these alleles for genetic predisposition to MS. In this study nt's are numbered from the transcription start site and aa numbers are given for the unprocessed precursor. The nt designations utilized by Gololeva et al 23 are given in brackets for comparison.
IFNA2 gene:
The polymorphisms presumed at nt 137 (1068) and 170 (1101) within the IFNA2 gene were not confirmed by screening the DNA of 84 MS patients by SSCP analysis. 
IFNA17:
The presumed polymorphism at nt position 170 (1101) could not be confirmed by SSCP-screening and by directly sequencing the PCR products of four individuals apparently heterozygous for the DNA fragments analyzed. Instead, an insertion of Adenine after nt 170 was observed resulting in a frameshift and a subsequent stop at codon position 58. The novel polymorphism is analyzed by PCR amplification and restriction enzyme digestion since the insertion of Adenine destroys the NlaIII recognition site. The IFNA17 [171InsA] allele was absent in 106 controls but present in four out of 59 MS patients with different courses of the disease, RRMS (1/31), SPMS (1/18) and PPMS (2/7). The study was extended to 78 patients with PPMS and an allele carrier frequency of 10.3% (RR = 25.68; 95% CI = 10.3-63.5; P c Ͻ 0.06) was estimated. Seven patients were heterozygous and one patient was homozygous for the predisposing allele.
The second polymorphism within the IFNA17 gene 
Haplotypes identified by LD analysis
The IFN gene cluster spans a region of approximately 400 kb, with IFNB and IFNWP19 representing the most distally and proximally located genes. 24 Since the genetic distance between IFNB1 and D9S126 in the gene order IFNB1 -IFNA -D9S126 has been estimated as comprising 4.4 cM, the distance between IFNB and IFNA must be less. 25 Based on the physical order of the IFN genes two-point LD were calculated between the diallelic polymorphisms in the IFNB, IFNA10, IFNA17 genes and the intergenic (GT) n microsatellite. The physical distance is approximately 200 kb between IFNB and IFNA10, 45 kb between IFNA10 and IFNA17 while the physical distance between IFNA17 and the IFNA microsatellite is not known. As shown in Table 4 
Discussion
The aim of the present study was to clarify: (1) whether polymorphism(s) within the IFNB gene itself may explain the therapeutical benefit of IFN␤ in MS patients, (2) whether the previously observed protective effect of the IFNA [02] allele is linked to polymorphism(s) within the IFNB gene, or (3) to polymorphism(s) within the IFNA genes. The 5′ and 3′ UTR of the IFNB gene are well characterized. [20] [21] [22] We covered these regions by SSCP analysis. Functionally relevant polymorphisms in cis-regulatory elements correlating with insufficient IFNB expression were excluded. The coding region was analyzed to detect polymorphisms which could influence receptor ligand interaction and modify signal transduction by insufficient conformational changes of the IFNR. No functionally relevant polymorphisms were identified. The high efficiency of SSCP analysis to detect MPSV has been reviewed recently, 26 in fact a polymorphism within the coding region of the IFNB gene, albeit non-functional, could be identified by this method. Excluding polymorphism(s) within the IFNB gene in the Caucasian population indicates that NAB production towards IFN␤-1a could not be attributed to sequence variation in the recombinant protein. Even though antibody production tends to be higher against recombinant proteins not identical with the host, induction of antibodies may also depend on additional factors. Contaminating proteins of the IFN preparation may act as adjuvant for a stimulatory response against self or modified-self proteins. The individual specific background, thought to play a role in a variety of autoimmune diseases with known or unknown autoantibody production may also be responsible. This hypothesis is underscored by the observation that antibody production against rIFN␣-2a differs in ethnic groups, ie, 39% of Asian patients develop antibodies but only 14% of Caucasians. 19 A multicenter study accompanying a clinical trial of IFN␤-1a (Rebif ® ) therapy may contribute to unravel the genetic background predisposing for antibody production (C Hardt).
Even though polymorphisms within cis-regulatory elements of the IFNB gene are now excluded in MS predisposition, only preliminary data are available on polymorphisms within transregulatory genes, activators (ATF-2, IRF-1, NF-B) or repressors (IRF-2, NRF-1, NRF-2) of transcription. A microsatellite within the IRF-1 gene has been analyzed previously but evidence for genetic predisposition was not obtained 1 while analysis of a microsatellite adjacent to the IRF-2 gene provides weak MS association in HLA-DRB1*03 individuals.
1 Impaired IFN responses might also be related to polymorphism(s) within the IFNR genes. Analyzing more than 500 MS patients and 400 controls for a microsatellite located in intron 5 of the IFNAR1 gene did not indicate disease association with MS (Miterski et al, unpublished) .
So far, the intergenic IFNA microsatellite has been analyzed by two groups. 1, 27 In the Swedish study no linkage was observed between MS and the genetic marker tested. 27 In the present association study including 505 patients and 369 controls our analysis revealed significant protection from MS for allele carrier of the IFNA [02] allele and an increased risk for carrier of the IFNA [07] allele. Association studies are more sensitive than linkage analysis 28 and may explain the different outcomes. Additional evidence for a candidate gene within the IFN region was obtained by LD analysis of the IFNA microsatellite and the IFNB gene polymorphism providing significant LD in the patient but not control cohort. Therefore suspected or already confirmed polymorphisms were analyzed within the IFNA genes as listed in Golovleva et al. 23 In agreement with the Swedish study, we could not confirm IFNA2 nt 137 (1068) and nt 170 (1101) as polymorphic sites. The IFNA10 gene has been shown to be polymorphic in the Swedish population. One allele is functional, while the second allele is nonfunctional, due to a nt substitution in position 60 (991) . Since the polymorphism in nt 522 does not result in an aa substitution our analysis was restricted to the polymorphism at nt 551. The frequency of the IFNA17 [551G] allele was 21% in Germans and differs in ethnic groups, like Swedes (11%), Finns (24%), Saamis (29%), Indians (25%), African Blacks (32%) and Chinese (50%). 29 At present no information is available, if this polymorphism will modify functional activity of IFNA17. The presumed polymorphism at nt 170 (1101) within the IFNA17 gene was neither confirmed in the Swedish 23 nor in the German population. Instead a novel polymorphism was identified in the German MS patients. The nt 170 was followed by an A insertion causing a frame shift and immediate stop codon. The non-functional allele was not observed in the control cohort but was present in MS patients (PPMS = 10.3%; SPMS = 5.6%; RRMS = 3.2%). Since homozygosity of the non-functional allele was observed in only one patient, two hypotheses, ie, gain of function and allelic heterogeneity, should be discussed to explain functional consequences. After proteolytic cleavage of the signal peptide, the truncated protein would consist of only 30 aa. As proposed by Uzé et al 30 31 So far, the exact location of the intergenic microsatellite within the IFN region is not known. LD data obtained in this study provide evidence, that the (GT) n repetition is located centromeric, close to the IFNA17 gene. Thus the LD values expressed as ⌬rel are 0.86 between the IFNA10 and the IFNA17 genes (45 kb apart), while the average ⌬rel was close to 0.86 between IFNA17 and the IFNA microsatellite marker. Analysing presumable or already known polymorphisms in different IFNA genes did not provide an explanation for the disease associated haplotype except for IFNA17 as discussed above. LD analyses supports IFNA14, IFNA16 and IFNA5 as the most likely candidate genes as deduced from their location. However, at present genes located closer to the centromere cannot be excluded. Information on differential expression and distinct functional activity of the 13 different IFNA genes is little. In an extensive study Khan et al 32 analyzed immunoreactive IFN-␣ in paraffin-embedded tissue of 36 different organs from over 300 individuals without evidence of viral infections. Tissue histiocytes from virtually all organs were positive. Highly purified leukocyte IFN-␣ preparations contained at least nine different IFN␣ species: IFN␣-1a, ␣-2b, ␣-4b, ␣-7a, ␣-8b, ␣-10a, ␣-14c, ␣-17b, ␣-21b. 33 IFN␣-1a was the major subtype, comprising ෂ30% of total leukocyte IFN␣. IFN␣-14c is the only subtype with potential N-glycosylation sites. Given the constitutive and abundant expression of IFNA in all tissues, the IFNA genes may be envisaged not only as a redundant system for antiviral activity. IFN genes may have diverged in evolution to serve specific functions which may not only be related to viral infections. The pleiotropic activities of IFNs are mediated through transcriptional regulation of more than hundred downstream effector genes. 34 Using oligonucleotide arrays genes differentially regulated by IFN␣-2a, IFN␤ and IFN␥ have been identified and overlapping as well as specific activities were evident. 34 The same approach would be suitable to dissect the functional activities of the different IFN␣ subtypes provided highly purified or recombinant protein is available. From a functional point of view one would expect that IFNA genes with less redundant and more specific activities would be the most likely candidates in MS predisposition. Even though this seems to be a quite elegant method to choose a candidate for genetic analysis, additional information would be required. Multiple time points of mRNA transcription and tissue specific expression of IFNA inducible genes have to be considered. Therefore screening the IFNA genes for polymorphism straightway seems to be more feasible at present.
Materials and methods
Probands
Peripheral blood samples from more than 400 healthy blood donors were kindly provided by Drs Kü hnl, Benn and Darda (University Hospital Eppendorf, Transplantation Immunology, Hamburg, Germany). MS patients were thoroughly examined by the members of the Multiple Sclerosis study group. Blood samples of more than 400 unrelated MS patients visiting the Departments of Neurology in the University clinics of Bochum and Gö ttingen (Germany) were included in this study. Both cohorts have been described in detail previously, including DNA extraction and HLA-DRB1* typing. P]-dCTP. After an initial denaturation for 5 min at 94°C, denaturation was reduced to 1 min in the following cycles. Annealing time was always 1 min but temperature was decreased 3°C per cycle in the first two annealing steps to generate highly specific templates in the beginning. Extension was at 72°C for 1 min and was increased to 5 min in the last cycle. Restriction enzyme digestion of PCR products for SSCP or PCR-RFLP analysis was performed according to the manufacturer's recommendation.
Gel electrophoresis conditions for SSCP analysis have been described in detail recently. 26 The gel matrix consists of 5% polyacrylamide and 2-5% glycerol. Single stranded DNA was detected by radioactively labeling PCR fragments during the amplification process and autoradiography after gel electrophoresis and drying. Genotyping for the IFNA microsatellite was also performed by radioactively labeling amplification products directly in the PCR. PCR fragments were denatured and applied to a denaturing 5-6% polyacrylamide gel containing 7 m urea. Alleles were determined after autoradiography by comparing fragment mobility with an already known standard. Utilizing the same electrophoresis conditions, internal radioactive labeling of the PCR-products and restriction enzyme digestion, the IFNA10 polymorphism was detected by PCR-RFLP. Determination of the IFNA17 polymorphisms did not require internal labeling, since restriction enzyme digested PCR fragments could be resolved on 1.5% horizontal agarose gels. Following ethidiumbromide staining results were documented by a gel documentation system (Intas, Gö ttingen, Germany). Confirmation of polymorphisms detected by SSCP analysis was achieved by directly sequencing the PCR product of selected DNA's as described previously. 26 Cycle sequencing was carried out utilizing the Thermo Sequenase™ Dye Terminator Cycle Sequencing Kit (Amersham Pharmacia Biotech, Freiburg, Germany). Samples were applied to an ABI 373 automated sequencer and analyzed with the ABI 373 software, version 2.1 (Applied Biosystems GmbH, Weiterstadt, Germany).
Statistical analysis
Under the assumption, that alleles predisposing for the disease may be inherited codominantly or recessively, genotype and allele carrier frequencies were calculated with a program (dBASE III) kindly provided by Dr Charmley and modified to the present version (dBASE IV for windows) by R Manthey. The genotype frequency could provide the information for a recessive mode of inheritance of predisposing genes, if the number of homozygous individuals, either AA or BB is significantly higher in the patient group (risk) or control cohort (protection). On the other hand the allele carrier frequency is calculated under the hypothesis that the predisposing allele is inherited codominantly. Thus the carriage of one predisposing allele for a given gene might be sufficient, to increase the risk for the disease. The allele carrier frequency for A is calculated by dividing the number of AA and AB individuals by the number of individuals analyzed, the frequency for B is calculated accordingly. The relative risk (RR), etiologic fraction (EF) and preventive fraction (PF) were determined according to Svejgaard et al. 35 The etiologic fraction was introduced previously by Mietinen 36 and indicates at the population level how much a disease associated marker contributes to the development of a disease. The etiologic fraction is calculated for positive associations (RR = Ͼ1) by the formula:
where a = marker present in patients, b = marker absent in patients. As has been shown by Green, 37 the preventive fraction can be used for decreased risk (RR = Ͻ1) and is calculated by the formula: PF =
(1−RR) hp RR (1−hp) + hp Both the EF and PF values can vary between 0 (no association) and 1 (maximal association).
Stringent criteria were applied to prove statistical significance, ie, P-values are corrected (P c ) for the number of multiple comparisons. LD was calculated according to Arnold 
